Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 1, 2011, Pages 105-119

  Wu, Kai ^a   Looby, Michael ^b   Pillai, Goonaseelan ^b   Pinault, Gregory ^b   Drollman, Anton Franz ^b   Pascoe, Steve ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Circadian variation; Drug development; FEV1; Kinetic pharmacodynamic model

Indexed keywords

BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG RESEARCH; DRUG RESPONSE; FORCED EXPIRATORY VOLUME; LONGITUDINAL STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; SIGNAL NOISE RATIO; SIMULATION;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORCED EXPIRATORY VOLUME; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; SPIROMETRY; TIME FACTORS;

EID: 79551580131     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-010-9180-2     Document Type: Article

References (14)

1. Chen X, Mallikaarjun S (2005) Modeling of circadian effect on lung function in patients with chronic obstructive pulmonary disease. PAGE
2. American Thoracic Society. Standardization of spirometry, 1994 update (1995). Am J Respir Crit Care Med 152:1107-1136
3. J Gabrielsson W Jusko L Alari 2000 Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from the response profiles Biopharm Drug Dispos 21 41 52 1:CAS:528:DC%2BD3cXotlWmtLY%3D 10.1002/1099-081X(200003)21:2<41::AID- BDD217>3.0.CO;2-D 11100906
4. P Jacqmin E Snoeck EA van Schaick R Gieschke P Pillai JL Steimer P Girard 2006 Modeling response time profiles in the absence of drug concentrations; definition and performance evaluation of the K-PD model J Pharmacokinet Pharmacodyn 34 57 85 10.1007/s10928-006-9035-z 17051439
5. G Pillai R Gieschke T Goggin P Jacqmin RC Schimmer JL Steimer 2004 A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis Br J Clin Pharmacol 58 618 631 10.1111/j.1365-2125.2004.02224.x 15563360
6. PJ Barnes 1993 Muscarinic receptor subtypes in airways Life Sci 52 521 528 1:CAS:528:DyaK3sXhtFKrtL8%3D 10.1016/0024-3205(93)90310-Y 8441331
7. RA Pauwels AS Buist PM Calverley CR Jenkins SS Hurd GOLD Scientific Committee 2001 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary Am J Respir Crit Care Med 163 1256 1276 1:STN:280:DC%2BD3MzisFGqtw%3D%3D 11316667
8. Sheiner LB, Beal SL (1992) NONMEM user guide. University of California, San Francisco
9. L Lindbom P Pihlgren EN Jonsson 2005 PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM Comput Methods Programs Biomed 79 241 257 10.1016/j.cmpb.2005.04.005 16023764
10. Holford N (2005) The visual predictive check-superiority to standard diagnostic (Rorschach) plots. PAGE
11. MO Karlsson LB Sheiner 1993 The importance of modeling interoccasion variability in population pharmacokinetic analyses J Pharmacokinet Pharmacodyn 21 735 750 1:STN:280:DyaK2c7os12huw%3D%3D
12. MO Karlsson LB Sheiner 1994 Estimating bioavailability when clearance varies with time Clin Pharmacol Ther 55 623 637 1:STN:280:DyaK2c3ntlCiuw%3D%3D 10.1038/clpt.1994.79 8004879
13. R Lalonde D Ouellet EK Kimanani D Potvin LM Vaughan RM Hill 1999 Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability J Pharmacokinet Pharmacodyn 27 67 83 1:CAS:528:DyaK1MXlvVOmtb8%3D
14. I Matthews C Kirkpatrick N Holford 2004 Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides Br J Clin Pharmacol 58 8 19 1:CAS:528:DC%2BD2cXmtlGrsbo%3D 10.1111/j.1365-2125.2004. 02114.x 15206987